Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Cash & Current Investments (2021 - 2025)

Historic Cash & Current Investments for Rxo (RXO) over the last 5 years, with Q4 2025 value amounting to $17.0 million.

  • Rxo's Cash & Current Investments fell 5142.86% to $17.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $17.0 million, marking a year-over-year decrease of 5142.86%. This contributed to the annual value of $17.0 million for FY2025, which is 5142.86% down from last year.
  • As of Q4 2025, Rxo's Cash & Current Investments stood at $17.0 million, which was down 5142.86% from $25.0 million recorded in Q3 2025.
  • Rxo's 5-year Cash & Current Investments high stood at $187.0 million for Q3 2022, and its period low was $5.0 million during Q4 2023.
  • Moreover, its 5-year median value for Cash & Current Investments was $29.0 million (2021), whereas its average is $56.5 million.
  • As far as peak fluctuations go, Rxo's Cash & Current Investments plummeted by 9489.8% in 2023, and later surged by 60000.0% in 2024.
  • Over the past 5 years, Rxo's Cash & Current Investments (Quarter) stood at $29.0 million in 2021, then surged by 237.93% to $98.0 million in 2022, then tumbled by 94.9% to $5.0 million in 2023, then skyrocketed by 600.0% to $35.0 million in 2024, then crashed by 51.43% to $17.0 million in 2025.
  • Its last three reported values are $17.0 million in Q4 2025, $25.0 million for Q3 2025, and $18.0 million during Q2 2025.